Wave Life Sciences Ltd (WVE) Expected to Announce Earnings of -$0.97 Per Share
Analysts expect Wave Life Sciences Ltd (NASDAQ:WVE) to report ($0.97) earnings per share for the current fiscal quarter, according to Zacks Investment Research. Five analysts have issued estimates for Wave Life Sciences’ earnings. The highest EPS estimate is ($0.60) and the lowest is ($1.45). Wave Life Sciences posted earnings per share of ($1.23) during the same quarter last year, which indicates a positive year-over-year growth rate of 21.1%. The firm is expected to announce its next quarterly earnings results on Thursday, August 8th.
On average, analysts expect that Wave Life Sciences will report full year earnings of ($3.90) per share for the current financial year, with EPS estimates ranging from ($5.82) to ($1.69). For the next financial year, analysts expect that the business will post earnings of ($4.91) per share, with EPS estimates ranging from ($5.83) to ($3.58). Zacks’ earnings per share calculations are a mean average based on a survey of research firms that follow Wave Life Sciences.
Wave Life Sciences (NASDAQ:WVE) last announced its quarterly earnings data on Friday, May 10th. The company reported ($1.36) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.19) by ($0.17). The firm had revenue of $3.03 million during the quarter, compared to the consensus estimate of $9.66 million. Wave Life Sciences had a negative return on equity of 146.23% and a negative net margin of 971.48%.
In related news, insider Michael A. Panzara sold 7,000 shares of Wave Life Sciences stock in a transaction that occurred on Monday, March 11th. The shares were sold at an average price of $48.00, for a total transaction of $336,000.00. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, insider Paul Bolno sold 50,000 shares of Wave Life Sciences stock in a transaction that occurred on Friday, March 15th. The shares were sold at an average price of $45.48, for a total transaction of $2,274,000.00. The disclosure for this sale can be found here. Company insiders own 44.20% of the company’s stock.
A number of hedge funds have recently modified their holdings of the stock. Quantamental Technologies LLC purchased a new position in Wave Life Sciences in the fourth quarter worth $29,000. Citigroup Inc. lifted its stake in shares of Wave Life Sciences by 189.4% during the fourth quarter. Citigroup Inc. now owns 2,807 shares of the company’s stock worth $118,000 after buying an additional 1,837 shares during the period. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. lifted its stake in shares of Wave Life Sciences by 17.9% during the first quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. now owns 3,045 shares of the company’s stock worth $118,000 after buying an additional 462 shares during the period. Amundi Pioneer Asset Management Inc. lifted its stake in shares of Wave Life Sciences by 45.0% during the fourth quarter. Amundi Pioneer Asset Management Inc. now owns 2,900 shares of the company’s stock worth $122,000 after buying an additional 900 shares during the period. Finally, Legal & General Group Plc lifted its stake in shares of Wave Life Sciences by 17.9% during the fourth quarter. Legal & General Group Plc now owns 3,094 shares of the company’s stock worth $130,000 after buying an additional 469 shares during the period. 75.37% of the stock is currently owned by institutional investors.
NASDAQ WVE traded down $0.67 during trading on Wednesday, hitting $27.05. The stock had a trading volume of 328,687 shares, compared to its average volume of 463,354. The company has a debt-to-equity ratio of 0.13, a current ratio of 1.56 and a quick ratio of 1.56. The company has a market cap of $927.77 million, a P/E ratio of -5.33 and a beta of 0.56. Wave Life Sciences has a one year low of $22.90 and a one year high of $56.00.
About Wave Life Sciences
Wave Life Sciences Ltd., a clinical stage genetic medicine company, designs, optimizes, and produces of novel stereopure oligonucleotides through PRISM, a discovery and drug developing platform. The company is primarily developing oligonucleotides that target genetic defects to either reduce the expression of disease-promoting proteins or transform the production of dysfunctional mutant proteins into the production of functional proteins.
Featured Article: Closed-End Mutual Funds
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Wave Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Wave Life Sciences and related companies with MarketBeat.com's FREE daily email newsletter.